ATG5 and cancer: Indeed, recent studies in skeletal muscle and cancer cells reported that pharmacological activation of REV-ERBα inhibits autophagosome formation via negative modulation of core autophagy genes such as Ulk3, Ulk1, Bec1, Atg7, and Atg5 [17, 18].